Danegaptide在急性心肌梗死直接PCI中的2期随机临床试验
本研究为2期随机临床试验,纳入585例STEMI患者,随机接受danegaptide高剂量、低剂量或安慰剂,主要终点为3个月心脏MRI评估的心肌挽救。结果显示danegaptide未改善心肌挽救指数、最终梗死面积或左心室射血分数,临床结局也无差异。
要点
- 在STEMI直接PCI患者中,danegaptide未改善3个月心肌挽救指数。
- danegaptide未减少最终梗死面积或改善左心室射血分数。
- danegaptide组与安慰剂组临床结局无差异。
核心结论
- 对于STEMI行直接PCI的患者,给予danegaptide未改善心肌挽救。
研究设计与样本
- 2期随机临床试验,2013年11月至2015年8月共随机纳入585例STEMI患者。
- 纳入标准为TIMI血流0-1级、单支血管病变、缺血时间小于6小时。
主要发现
- 心肌挽救指数:高剂量组63.9±14.9,低剂量组65.6±15.6,对照组66.7±11.7,P=0.40。
- 最终梗死面积:高剂量组19.6±11.4 g,低剂量组18.6±9.6 g,对照组21.4±15.0 g,P=0.88。
- 左心室射血分数:高剂量组53.9%±9.5%,低剂量组52.7%±10.3%,对照组52.1%±10.9%,P=0.64。
- 组间临床结局无差异。
临床怎么用
- 目前证据不支持在STEMI直接PCI患者中使用danegaptide以改善心肌挽救。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Reperfusion immediately after reopening of the infarct-related artery in ST-segment elevation myocardial infarction (STEMI) may cause myocardial damage in addition to the ischaemic insult (reperfusion injury). The gap junction modulating peptide danegaptide has in animal models reduced this injury. We evaluated the effect of danegaptide on myocardial salvage in patients with STEMI. METHODS: In addition to primary percutaneous coronary intervention in STEMI patients with thrombolysis in myocardial infarction flow 0-1, single vessel disease and ischaemia time less than 6 hours, we tested, in a clinical proof-of-concept study, the therapeutic potential of danegaptide at two-dose levels. Primary outcome was myocardial salvage evaluated by cardiac MRI after 3 months. RESULTS: From November 2013 to August 2015, a total of 585 patients were randomly enrolled in the trial. Imaging criteria were fulfilled for 79 (high dose), 80 (low dose) and 84 (placebo) patients eligible for the per-protocol analysis. Danegaptide did not affect the myocardial salvage index (danegaptide high (63.9±14.9), danegaptide low (65.6±15.6) and control (66.7±11.7), P=0.40), final infarct size (danegaptide high (19.6±11.4 g), danegaptide low (18.6±9.6 g) and control (21.4±15.0 g), P=0.88) or left ventricular ejection fraction (danegaptide high (53.9%±9.5%), danegaptide low (52.7%±10.3%) and control (52.1%±10.9%), P=0.64). There was no difference between groups with regard to clinical outcome. CONCLUSIONS: Administration of danegaptide to patients with STEMI did not improve myocardial salvage. TRIAL REGISTRATION NUMBER: NCT01977755; Pre-results.
引用
- Engstrøm T, Nepper-Christensen L, Helqvist S, et al. Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2 randomised clinical trial. Heart. 2018. PMID: 29602883. doi:10.1136/heartjnl-2017-312774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。